Apricus Biosciences [NASDAQ:APRI] ex NEXM - Tomo 2
- Creatore Discussione n3xt
- Data di inizio
- Registrato
- 24/3/10
- Messaggi
- 11.678
- Punti reazioni
- 152
sono rientrato da dove ero uscito,,, stavolta piu di un chip
diciottodieci
2000credici
- Registrato
- 25/11/08
- Messaggi
- 13.303
- Punti reazioni
- 284
2.20 +1.39%
- Registrato
- 24/3/10
- Messaggi
- 11.678
- Punti reazioni
- 152
diciottodieci
2000credici
- Registrato
- 25/11/08
- Messaggi
- 13.303
- Punti reazioni
- 284
ma sei un fan di 007??
di Sean Connery...e di Ursula (forever)
che oggi è, purtroppo, ridotta molto male...è triste, ma il tempo passa per tutti...sono meglio i ricordi ...come eravamo...
Considera i miei quasi 13 Lustri e capirai perchè...Mi dovrò interfacciare necessariamente, fra non molto, con l'immagine di Dx...anche se preferirei un Centro/Destra, finchè sarà possibile...
Allegati
Ultima modifica:
diciottodieci
2000credici
- Registrato
- 25/11/08
- Messaggi
- 13.303
- Punti reazioni
- 284
Se poi consideri come era ai bei tempi...c'è da...
Quindi meglio ricordarla così
Quindi meglio ricordarla così
- Registrato
- 24/3/10
- Messaggi
- 11.678
- Punti reazioni
- 152
SAN DIEGO--(BUSINESS WIRE)--Apricus Biosciences, Inc., (“Apricus Bio”) (Nasdaq: APRI) today announced data from animal studies showing that the NexACT® technology significantly improved the oral delivery of five small molecule drugs tested, with the best improvements up to 20-fold, in terms of improvement in absorption. A total of 10 small molecule therapeutic drugs with known low solubility and/or permeability, according to the Biopharmaceuticals (“BCS”) Classification System, were selected for these studies, and represented the following classes: anti-inflammatory drugs, diuretics, anti-hypertensives, antibiotics, anti-psychotics, anti-Parkinson agents and proton pump inhibitors.
The BCS, developed by Professor Gordon L. Amidon from the College of Pharmacy at the University of Michigan, separates drugs into four quadrants depending on their solubility and permeability. Class 1 drugs are high solubility and high permeability, Class 2 low solubility and high permeability, Class 3 high solubility and low permeability, and Class 4 low solubility and low permeability. In the Apricus Bio studies, the compounds that showed the most improvement when formulated with the NEXACT technology were in Classes 2 and 4, where solubility is a determining factor.
Commenting on today’s news, Dr. Bassam Damaj, President and Chief Executive Officer of Apricus Bio, stated, “Drugs are classified according to their solubility and permeability. This early data shows that the inclusion of NexACT can significantly improve the oral delivery of some small molecules by positively affecting their solubility, which affects absorption. Over time, this could open up exciting new partnership opportunities, especially for promising drug candidates that did not reach, or successfully pass through clinical development, because of poor solubility. Our goal is to make a major breakthrough in the utilization of NexACT to improve and/or enable the delivery of difficult-to-absorb compounds.”
The BCS, developed by Professor Gordon L. Amidon from the College of Pharmacy at the University of Michigan, separates drugs into four quadrants depending on their solubility and permeability. Class 1 drugs are high solubility and high permeability, Class 2 low solubility and high permeability, Class 3 high solubility and low permeability, and Class 4 low solubility and low permeability. In the Apricus Bio studies, the compounds that showed the most improvement when formulated with the NEXACT technology were in Classes 2 and 4, where solubility is a determining factor.
Commenting on today’s news, Dr. Bassam Damaj, President and Chief Executive Officer of Apricus Bio, stated, “Drugs are classified according to their solubility and permeability. This early data shows that the inclusion of NexACT can significantly improve the oral delivery of some small molecules by positively affecting their solubility, which affects absorption. Over time, this could open up exciting new partnership opportunities, especially for promising drug candidates that did not reach, or successfully pass through clinical development, because of poor solubility. Our goal is to make a major breakthrough in the utilization of NexACT to improve and/or enable the delivery of difficult-to-absorb compounds.”
Se poi consideri come era ai bei tempi...c'è da...
Quindi meglio ricordarla così
Bene, si vede che postare delle fiKe porta bene!!!
2,65
bene,
vediamo se adesso si mette in trend e andiamo davvero su... oggi deve chiudere sui massimi senza tentennamenti ben sopra 2,60
la prossima settimana capiremo meglio
- Registrato
- 24/3/10
- Messaggi
- 11.678
- Punti reazioni
- 152
uscito
- Registrato
- 24/3/10
- Messaggi
- 11.678
- Punti reazioni
- 152
al 90% hai fatto bene
boh....in gain sempre bene....ma si sono mangiato anche mezzo tappo a 2,69
boh....in gain sempre bene....ma si sono mangiato anche mezzo tappo a 2,69
infatti ho scritto al 90%
Groundbreaking Drug, Solid Management Make Apricus Bio a Compelling Buy
Investing in small sized biotech companies can be a risky endeavor. These companies often have few products, no revenues, and everything resting on the approval of a single drug. Apricus Biosciences, Inc. “Apricus Bio” (APRI) offers something very different for investors. The company boasts an arsenal of over a dozen diverse products, dealing with a wide range of health issues including cancer, diabetes, sexual dysfunction, inflammation, among others. But there are several other factors that make Apricus Bio a particularly interesting investment. The company already has an approved groundbreaking drug, very valuable and clinically validated core technology, and a solid management team that has proven it can deliver.
Vitaros®
On Monday Health Canada approved the company’s first drug, Vitaros®, a topical drug used to treat erectile dysfunction. Utilizing the company’s NexACT® technology, Vitaros® works by simply applying a drop of gel to the skin.
“The drug itself is a major breakthrough in the erectile dysfunction world,” stated Apricus Bio CEO Dr. Bassam Damaj, in an interview following the approval. He added that the treatment is simple, safer, and a faster acting drug than existing treatments.
The drug is even safe for use by patients with hypertension, diabetes, cardiac problems, and many others who are often unable to safely use traditional oral treatments. Vitaros® has been shown to work within a couple of minutes, compared to the typical 30 minutes to two hour delay from oral medications. This is quite a remarkable medical feat and one that is sure to pique the interest of patients. Company market research also indicates that urologists would prescribe the drug to up to 30% of their patients diagnosed with erectile dysfunction—not a bad number in a $2 billion ex-US market. The company plans to use the recent approval to move forward in getting Vitaros® into over 100 international markets.
NexACT® Technology
Vitaros® is able to deliver compounds to the body by effectively penetrating through the skin, something topical treatments often have trouble achieving. The key to this breakthrough derives from the company’s innovative NexACT® technology, which may be the real value behind Apricus Bio. NexACT® utilizes proprietary, ‘permeation enhancers’ that are biodegradable, biocompatible, and non-toxic. They mimic the composition of human tissues which allows them to pass through organic barriers such as skin, to more effectively deliver and target drugs to areas of the body. What makes NexACT® so valuable is that Apricus Bio can leverage the technology by applying it to already existing compounds to create new patentable products that deliver drugs safer than current methods.
The technology has also proven itself to be extremely safe. It has been used on over 5,000 patients and has been through almost a half dozen clinical trials. With all this, there has been zero serious drug safety related issues reported. Furthermore, NexACT® has now been fully validated with the approval of Vitaros®, solidifying the technology’s safety and effectiveness.
“It is definitely a game-changer for our company,” Dr. Damaj stated, referring to the Vitaros® approval. “Clinical validation is what we needed.”
Now that a drug utilizing NexACT® has been approved, the company can start focusing on out-licensing its now proven technology, building revenues, and the commercialization of their products.
Management
Apricus Bio also has solid leadership and has accomplished a great deal in its first year. Leading the company is Dr. Bassam Damaj, who took over as CEO in December 2009. Since then, the company has gained NASDAQ compliance and won approval of its first drug. An important achievement has also been increasing the value of NexACT®. When Dr. Damaj first took over the company a year ago, the technology was able to deliver drugs through only 1 route into the body for 1 class of drugs. Now, it is capable of delivering compounds through 5 routes and covers 6 classes of drugs. This increased versatility allows the company to license the technology to a far wider array of partners that can utilize the technology with their own proprietary compounds.
Dr. Damaj is also a very knowledgeable and well respected professional in the field. In the early 2000s, he was approached by the U.S. government. The military was in search of a technology that could detect Anthrax and its level of infection in the human body. Remarkably, Dr. Damaj was able to deliver this kit—the first of its kind—in less than six months, winning him a U.S. Congressional Award in 2002. This is a testament to the respect and talents of the Apricus Bio leadership.
Dr. Damaj’s present goal is focusing on Apricus Bio and monetizing the company’s many products. The company’s pipeline includes many promising drugs including PrevOnco for treatment of liver cancer and Femprox®, a topical cream for patients with female sexual arousal disorder. What frustrates him, however, is what he sees as the undervaluing of the company. He explained, “People don’t understand the power of our technology.” In his view, there is the potential for NexACT® to be utilized by a very large number of companies and products. In fact, Dr. Damaj stated that Apricus Bio is already in 22 active partnering discussions (Yes, 22). Many of these are described as being in the ‘late stages’. Confident in their products, the company expects to have a partnership deal in place by the end of this year. This partnership will open the floodgates to a multitude of subsequent deals to follow in 2011. These will include upfront payments, milestones, and back-end royalty rates.
In a crowded room of biotech companies, Apricus Bio boasts a broad, strong, and unique product portfolio. What makes this company a relatively safe investment is that they are utilizing already proven and effective treatments and blending them with their unique NexACT® technology to create new drugs that can be delivered easier, safer, and more effectively. With the approval of their first drug, it is now a clinically validated and proven technology. NexACT®’s versatility allows it to be partnered multiple times to multiple entities. Best of all, the Apricus Bio already has their first drug approved with partnerships and licensing to follow. There is much hidden value here that has yet to be realized, but the company has the proper management team and has shown it can deliver. With a current market cap of only $40 million, Apricus Bio is sorely undervalued at current levels.
Disclosure: Long APRI
About the author: Dustin Moore
Dustin Moore is a freelance writer focusing on smaller companies. He enjoys finding and exploring under-the-radar stocks. His preferred style is thoroughly researching one company at a time, rather than skimming the surface on several.
25
Followers9
Following
Follow
Send Message
Print Email Recommend 1
Share
3
Investing in small sized biotech companies can be a risky endeavor. These companies often have few products, no revenues, and everything resting on the approval of a single drug. Apricus Biosciences, Inc. “Apricus Bio” (APRI) offers something very different for investors. The company boasts an arsenal of over a dozen diverse products, dealing with a wide range of health issues including cancer, diabetes, sexual dysfunction, inflammation, among others. But there are several other factors that make Apricus Bio a particularly interesting investment. The company already has an approved groundbreaking drug, very valuable and clinically validated core technology, and a solid management team that has proven it can deliver.
Vitaros®
On Monday Health Canada approved the company’s first drug, Vitaros®, a topical drug used to treat erectile dysfunction. Utilizing the company’s NexACT® technology, Vitaros® works by simply applying a drop of gel to the skin.
“The drug itself is a major breakthrough in the erectile dysfunction world,” stated Apricus Bio CEO Dr. Bassam Damaj, in an interview following the approval. He added that the treatment is simple, safer, and a faster acting drug than existing treatments.
The drug is even safe for use by patients with hypertension, diabetes, cardiac problems, and many others who are often unable to safely use traditional oral treatments. Vitaros® has been shown to work within a couple of minutes, compared to the typical 30 minutes to two hour delay from oral medications. This is quite a remarkable medical feat and one that is sure to pique the interest of patients. Company market research also indicates that urologists would prescribe the drug to up to 30% of their patients diagnosed with erectile dysfunction—not a bad number in a $2 billion ex-US market. The company plans to use the recent approval to move forward in getting Vitaros® into over 100 international markets.
NexACT® Technology
Vitaros® is able to deliver compounds to the body by effectively penetrating through the skin, something topical treatments often have trouble achieving. The key to this breakthrough derives from the company’s innovative NexACT® technology, which may be the real value behind Apricus Bio. NexACT® utilizes proprietary, ‘permeation enhancers’ that are biodegradable, biocompatible, and non-toxic. They mimic the composition of human tissues which allows them to pass through organic barriers such as skin, to more effectively deliver and target drugs to areas of the body. What makes NexACT® so valuable is that Apricus Bio can leverage the technology by applying it to already existing compounds to create new patentable products that deliver drugs safer than current methods.
The technology has also proven itself to be extremely safe. It has been used on over 5,000 patients and has been through almost a half dozen clinical trials. With all this, there has been zero serious drug safety related issues reported. Furthermore, NexACT® has now been fully validated with the approval of Vitaros®, solidifying the technology’s safety and effectiveness.
“It is definitely a game-changer for our company,” Dr. Damaj stated, referring to the Vitaros® approval. “Clinical validation is what we needed.”
Now that a drug utilizing NexACT® has been approved, the company can start focusing on out-licensing its now proven technology, building revenues, and the commercialization of their products.
Management
Apricus Bio also has solid leadership and has accomplished a great deal in its first year. Leading the company is Dr. Bassam Damaj, who took over as CEO in December 2009. Since then, the company has gained NASDAQ compliance and won approval of its first drug. An important achievement has also been increasing the value of NexACT®. When Dr. Damaj first took over the company a year ago, the technology was able to deliver drugs through only 1 route into the body for 1 class of drugs. Now, it is capable of delivering compounds through 5 routes and covers 6 classes of drugs. This increased versatility allows the company to license the technology to a far wider array of partners that can utilize the technology with their own proprietary compounds.
Dr. Damaj is also a very knowledgeable and well respected professional in the field. In the early 2000s, he was approached by the U.S. government. The military was in search of a technology that could detect Anthrax and its level of infection in the human body. Remarkably, Dr. Damaj was able to deliver this kit—the first of its kind—in less than six months, winning him a U.S. Congressional Award in 2002. This is a testament to the respect and talents of the Apricus Bio leadership.
Dr. Damaj’s present goal is focusing on Apricus Bio and monetizing the company’s many products. The company’s pipeline includes many promising drugs including PrevOnco for treatment of liver cancer and Femprox®, a topical cream for patients with female sexual arousal disorder. What frustrates him, however, is what he sees as the undervaluing of the company. He explained, “People don’t understand the power of our technology.” In his view, there is the potential for NexACT® to be utilized by a very large number of companies and products. In fact, Dr. Damaj stated that Apricus Bio is already in 22 active partnering discussions (Yes, 22). Many of these are described as being in the ‘late stages’. Confident in their products, the company expects to have a partnership deal in place by the end of this year. This partnership will open the floodgates to a multitude of subsequent deals to follow in 2011. These will include upfront payments, milestones, and back-end royalty rates.
In a crowded room of biotech companies, Apricus Bio boasts a broad, strong, and unique product portfolio. What makes this company a relatively safe investment is that they are utilizing already proven and effective treatments and blending them with their unique NexACT® technology to create new drugs that can be delivered easier, safer, and more effectively. With the approval of their first drug, it is now a clinically validated and proven technology. NexACT®’s versatility allows it to be partnered multiple times to multiple entities. Best of all, the Apricus Bio already has their first drug approved with partnerships and licensing to follow. There is much hidden value here that has yet to be realized, but the company has the proper management team and has shown it can deliver. With a current market cap of only $40 million, Apricus Bio is sorely undervalued at current levels.
Disclosure: Long APRI
About the author: Dustin Moore
Dustin Moore is a freelance writer focusing on smaller companies. He enjoys finding and exploring under-the-radar stocks. His preferred style is thoroughly researching one company at a time, rather than skimming the surface on several.
25
Followers9
Following
Follow
Send Message
Print Email Recommend 1
Share
3
- Registrato
- 24/3/10
- Messaggi
- 11.678
- Punti reazioni
- 152
infatti ho scritto al 90%
lo stesso ho fatto con astm...sono uscito a 2,5 da 2 e poi in 6 gg ha fatto +100
sescri
FUORIDALL'EUROSUBITO
- Registrato
- 27/3/10
- Messaggi
- 4.976
- Punti reazioni
- 154
lo stesso ho fatto con astm...sono uscito a 2,5 da 2 e poi in 6 gg ha fatto +100
Speriamo che si ripeti
lo stesso ho fatto con astm...sono uscito a 2,5 da 2 e poi in 6 gg ha fatto +100
graficamente la tua uscita è ineccepibile e le biokakke di solito utilizzano questi UP per piazzare a mercato diluizioni e porcate varie incastrando i polli sul massimo di periodo
se fossi stato in gain avrei liquidato il 50% della posizione
- Registrato
- 24/3/10
- Messaggi
- 11.678
- Punti reazioni
- 152
sescri
FUORIDALL'EUROSUBITO
- Registrato
- 27/3/10
- Messaggi
- 4.976
- Punti reazioni
- 154